Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”
American Heart Journal Plus: Cardiology Research and Practice
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Citation
Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”. // American Heart Journal Plus: Cardiology Research and Practice. – URL: https://www.sciencedirect.com/science/article/pii/S2666602226002417?dgcid=rss_sd_all
Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”. American Heart Journal Plus: Cardiology Research and Practice. https://www.sciencedirect.com/science/article/pii/S2666602226002417?dgcid=rss_sd_all
“Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”.” American Heart Journal Plus: Cardiology Research and Practice.
@article{article88287,
title = {Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”},
journal = {American Heart Journal Plus: Cardiology Research and Practice},
url = {https://www.sciencedirect.com/science/article/pii/S2666602226002417?dgcid=rss_sd_all}
}